Gilead Sciences, Inc. (GILD) — closed signal from October 31, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 29, 2026.
Predicted vs. what happened
What happened
Reached its target in 84 days.
The thesis — published October 31, 2025
Gilead beat expectations and now thinks HIV sales will grow about 5% this year. Sales of Veklury fell 60% compared to last year, which drags results. The stock looks beaten down and could bounce back as investors see steadier HIV trends over the next 0-3 months. Still, progress in cancer drugs and any pricing news are key. Consider buying in small steps and wait for signs that more buyers are stepping in.
Primary drivers
- Company now expects HIV sales to grow about 5% this year.
- Shares look beaten down, which can set up a short-term bounce.
- Sales of Veklury fell sharply, which weighs on total results.
- Big, stable company that can hold up better in choppy markets.
How it played out
GILD: target reached in 84 days
On 2025-10-31, Lyra published GILD at $119.56 with expected growth of 12% and a target of $133.02. The thesis pointed to HIV sales growth of about 5% this year, a stock that looked beaten down, a sharp Veklury sales drop of 60%, and the support of a big, stable company in choppy markets.
Inside the window, GILD reached the target. It peaked at $141.71 on 2026-01-27, with a peak gain of 18.5%, and it took 84 days to get there. The stock ended the window at $139.55. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.